AURX
Nuo Therapeutics, Inc., a regenerative therapies company, develops, commercializes, and markets cell-based technologies that harness the regenerative capacity of the human body to trigger natural healing primarily in the United States. Its technology separates autologous blood to produce a platelet based therapy for the chronic wound care market. The company was formerly known as Cytomedix, Inc. and changed its name to Nuo Therapeutics, Inc. in November 2014. Nuo Therapeutics, Inc. was founded in 1998 and is based in Houston, Texas.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2026 Q1 | -0.01 | $1M | -$785,119 |
| 2025 Q4 | -0.01 | $1M | -$465,851 |
| 2025 Q3 | -0.01 | $1M | -$706,516 |
| 2025 Q2 | -0.01 | $700,202 | $260,699 |
| 2025 Q1 | -0.02 | $484,381 | -$228,059 |
| 2024 Q4 | -0.01 | $394,872 | -$490,539 |
| 2024 Q3 | -0.01 | $370,951 | -$638,329 |
| 2024 Q2 | -0.01 | $364,773 | -$695,267 |